跳至主要内容
临床试验/NCT01962077
NCT01962077已完成不适用

Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth

Hadassah Medical Organization2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Success of MedCem MTA pulpotomy in primary molar

研究概览

简要总结

assess the effect of MedCem MTA as a pulp medicament following pulpotomy in human primary molars with carious pulp exposure in comparison to Formocresol.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • healthy children
  • with Asymptomatic primary molars with a deep carious lesion;
  • Exposure of a vital pulp by caries;
  • No clinical or radiographic evidence of pulp degeneration, such as excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction,swelling, or sinus tract;
  • Ability to perform a leakage free restoration of the teeth using stainless steel crown, or amalgam/resin based restoration.

排除标准

  • 未提供

结局指标

主要结局

Success of MedCem MTA pulpotomy in primary molar

时间窗: Up to 36 months

No pain, no swelling or sinus tract, no internal root resorption progressing into the bone, no furcation and/or periapical bond destruction.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Comparison of MedCem MTA and Formocresol Used in... | 临床试验